Saxenda (liraglutide) is a glucagon-like peptide‑1 (GLP‑1) receptor agonist originally developed for type 2 diabetes and later approved in 2014 as the first daily GLP‑1 medication for weight loss

Mechanism of Action
Liraglutide mimics native GLP‑1 (97% homology), slowing gastric emptying, reducing hunger, increasing satiety via hypothalamic GLP‑1 receptors, and encouraging insulin release while suppressing glucagon in a glucose-dependent manne The acylated structure extends its half-life to ~13 hours, allowing once-daily dosing

Saxenda is a daily injectable GLP‑1 therapy that effectively supports weight loss by enhancing satiety and reducing appetite, supported by robust clinical data. Its use requires careful monitoring due to gastrointestinal side effects and rare but serious safety considerations, with clear protocols for dose escalation and discontinuation if ineffective.

Let me know if you'd like details on comparing it to other GLP‑1 injections (like Wegovy), strategies to manage side effects, or long-term sustainability insights!